CRDF Cardiff Oncology, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1213037 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY11.6%
TTM net income YoY25.3%
TTM EPS YoY31.6%
Revenue 3-yr CAGR6.7%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-7,068.2%
Net margin-6,735.2%
FCF margin—
EBITDA margin-7,005.5%
Returns
ROE-97.9%
ROA-75.2%
ROIC (approx.)-114.1%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets22.8%
Debt / equity0.00x
Current ratio4.21x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.06x
Accruals ratio4.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $593,000 | $683,000 | $488,000 | $386,000 | $359,000 |
| R&D expense | $35.33M | $36.85M | $32.86M | $27.11M | $17.38M |
| SG&A expense | $14.22M | $12.48M | $13.04M | $13.18M | $11.84M |
| Operating income | -$48.96M | -$48.65M | -$45.41M | -$39.90M | -$28.86M |
| Interest expense | — | — | — | — | $0 |
| Pretax income | -$45.85M | -$45.43M | — | — | — |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$45.85M | -$45.43M | -$41.44M | -$38.70M | -$28.29M |
| EBITDA | -$48.60M | -$48.25M | -$45.01M | -$39.67M | -$28.40M |
| EPS (basic) | -0.69 | -0.95 | -0.93 | -0.89 | -0.73 |
| EPS (diluted) | -0.69 | -0.95 | -0.93 | -0.89 | -0.73 |
| Weighted avg. shares (diluted) | 66.84M | 47.65M | 44.68M | 43.60M | 39.03M |
| Balance sheet | |||||
| Cash & equivalents | $17.47M | $51.47M | $21.66M | $16.35M | $11.94M |
| Short-term investments | $40.83M | $40.28M | $53.17M | $88.92M | $128.88M |
| Receivables | $182,000 | $773,000 | $288,000 | $771,000 | $535,000 |
| Current assets | $60.13M | $95.05M | $77.41M | $111.28M | $146.13M |
| PP&E, net | $578,000 | $898,000 | $1.24M | $1.27M | $382,000 |
| Total assets | $61.88M | $97.19M | $81.64M | $116.19M | $149.54M |
| Current liabilities | $16.39M | $13.43M | $10.44M | $7.81M | $6.56M |
| Total liabilities | $16.50M | $14.24M | $11.90M | $9.85M | $9.13M |
| Shareholders' equity | $45.39M | $82.95M | $69.74M | $106.34M | $140.42M |
| Shares outstanding | 68.31M | 66.52M | 44.68M | 44.68M | 41.96M |
| Cash flow statement | |||||
| Operating cash flow | -$37.92M | -$37.69M | -$30.89M | -$33.82M | -$23.04M |
| Capital expenditure | $44,000 | $80,000 | $582,000 | $1.01M | $205,000 |
| Free cash flow | -$37.97M | -$37.77M | -$31.47M | -$34.83M | -$23.25M |
| Investing cash flow | $1.34M | $13.73M | $36.20M | $38.15M | -$131.45M |
| Financing cash flow | $2.58M | $53.78M | $0 | $75,000 | $35.45M |
| Depreciation & amortization | $364,000 | $404,000 | $398,000 | $236,000 | $451,000 |
| Stock-based compensation | $5.69M | $4.76M | $4.51M | $4.26M | $3.23M |
Free plan shows the latest 5 periods; Pro shows all 25 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.